The Insulin Cost Reduction Act
Summary
The Insulin Cost Reduction Act This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.
Bill status
in committee
1 of 4 stages cleared
Introduction
Oct 2021
Committee Review
Floor Vote
President
Introduced Oct 19, 2021
Last action Oct 20, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
4
Key actions
0
Committee
3
Oct 20, 2021
Committee
Referred to the Subcommittee on Health.
lower
Oct 19, 2021
Committee
Referred to the Subcommittee on Health.
lower
Oct 19, 2021
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Oct 19, 2021
Introduced
Introduced in House
lower
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Glenn Grothman
RRepublican
Co
Chris Jacobs
RRepublican
Co
Rick W. Allen
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 5623
Scope: US
Hi! I can help you understand HR 5623. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline